Arkolith/Insider Trading/KZR/Form 4

Kirk Christopher J.

CEO, DirectorKezar Life Sciences, Inc. (KZR) · full profile →Form 4 · filed May 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
12
1 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 11, 2026Tender(U)43K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 11, 2026Disposed to issuer(D)4K—$00
May 11, 2026Disposed to issuer(D)18K—$00
May 11, 2026Disposed to issuer(D)9K—$00
May 11, 2026Disposed to issuer(D)7K—$00
May 11, 2026Disposed to issuer(D)87K—$00
May 11, 2026Disposed to issuer(D)120K—$00
May 11, 2026Disposed to issuer(D)9K—$00
May 11, 2026Disposed to issuer(D)12K—$00
May 11, 2026Disposed to issuer(D)26K—$00
May 11, 2026Disposed to issuer(D)17K—$00
May 11, 2026Disposed to issuer(D)19K—$00

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001744253-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML